The Latest Cardiac and Vascular News
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States Regulatory Filings for VERVE-101 in Second Half of 2022 Cash, Cash Equivalents and Marketable Securities […]
Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data for baxdrostat (CIN-107) in HALO Phase 2 trial for uncontrolled hypertension (uHTN) expected in 2H 2022 Phase 2 figHTN-CKD trial evaluating baxdrostat’s (CIN-107) utility in ameliorating complications of chronic kidney […]
SILVER SPRING, Md., May 09, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today provided a business update and reported financial results for the first quarter March 31, […]
Quanterix reports continued revenue growth as it scales to support transformational advances in neurology research BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced financial results for the three months ended March 31, 2022. “This is a […]
Heart failure patients implanted with Barostim can now receive conditional MRI scans MINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received U.S. Food and Drug Administration (FDA) approval for magnetic resonance […]
Medication Copayment and Insurance Premium Assistance Now Available for Medicare Patients GERMANTOWN, Md., May 9, 2022 /PRNewswire/ — The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, is pleased to announce that it has opened a new fund to assist individuals living with cardiomyopathy. Through the new […]
— First shipment of HAVs to six Ukrainian hospitals made today — — Product candidate to be used for civilian and military vascular trauma repair, the HAV’s lead investigational indication — DURHAM, N.C., May 09, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally […]
Phase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022 NEWTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced […]
Mavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers Study was conducted in parallel with ongoing Phase 3 EXPLORER-CN trial of mavacamten in obstructive hypertrophic cardiomyopathy to support regulatory approval in China SHANGHAI, China and PRINCETON, N.J., May 09, 2022 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN) […]
PARIS, May 09, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat hypertension and heart failure, announces today that it has recruited all planned patients in its phase III pivotal study FRESH, […]
